 The cost of manufacturing Soliris' monoclonal antibodies is less than "1 percent of the price of the drug," he said.Brazil's supreme court had decided in April 2018 to break the patent of Soliris in Brazil following local law.This medicine was only provided by the government's health system (SUS) and now it can be produced by other companies in that country.